Perimeter Medical Imaging AI (PINK) investor relations material

Key technology and product developments

• First FDA-approved AI-enabled imaging device for breast cancer surgery, addressing the high rate of reoperations in cancer surgeries.

• Optical coherence tomography (OCT) provides high-resolution, real-time imaging, enabling detection of cancer cells within critical tissue margins.

• AI layer automates image analysis, reducing surgeon workload and increasing confidence in margin assessment.

• Large proprietary image library and patented hardware create significant competitive moats.

• AI algorithm improvements are ongoing, enabled by a Predetermined Change Control Plan with the FDA.

Clinical and market impact

• Clinical trials met endpoints, demonstrating improved detection of positive margins and reducing need for second surgeries.

• Real-time feedback allows immediate surgical action, improving patient outcomes and reducing anxiety.

• Five-year survival rates are significantly higher when first surgeries achieve clean margins.

• Technology applicable to other solid tumor cancers beyond breast, with initial focus on U.S. breast cancer market.

• Surgeons and hospitals are adopting the technology, using it as a differentiator in their communities.

Business model and financials

• Recurring revenue model based on device placements, disposables (over 90% gross margin), service contracts, and software.

• Device can be sold (50% gross margin) or placed at no charge with cost recovery through procedure volume.

• No formal sales guidance provided due to early-stage variability.

• Total capital raised is approximately CAD 70 million, with about CAD 50 million invested in R&D.

• Strong insider ownership and recent capital raise with increased healthcare specialist participation.